TEL AVIV, ISRAEL AND RALEIGH, N.C.

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern Regulatory update Opaganib global Phase 2/3 […]

RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107’s unique host-targeted mechanisms of action hold potential versus Omicron and other variants – Phase 2/3 study sub-population analysis demonstrated a 62% reduction in mortality in moderately severe hospitalized patients; Data packages […]

– Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care – Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose selection, expected in Q1/ 22 – RHB-107 is a novel, investigational antiviral […]

62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm vs. 21 deaths in the 134-patient placebo arm; nominal p-value=0.019) 21% statistically significant efficacy benefit with opaganib in reaching room air by Day 14, the study primary endpoint […]

The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a novel antiviral serine protease inhibitor targeting human cell factors, is expected to […]

– COVID-19 and long COVID patients are at increased risk of developing kidney damage – Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model – Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to end-stage renal failure – Opaganib is a novel, late clinical-stage oral pill […]

– Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years – Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages – Movantik is the U.S. […]

– Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance 1  of approximately $71.5 million as of June 30, 2021 – Record Talicia® quarterly prescription volume up more than 10%; Movantik® quarterly new prescriptions up 5.6%; Talicia and Movantik coverage expanded to 8 and 9 out of 10 commercially insured Americans, […]

Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity    Opaganib’s unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect against other emerging variants, including the Delta (Indian) variant Completion of opaganib’s global fully enrolled 475-patient Phase 2/3…